Teva Pharmaceutical Industries Ltd ADR Stock
We can see a decrease in the price for Teva Pharmaceutical Industries Ltd ADR. Compared to yesterday it has lost -€0.300 (-1.170%).
With 22 Buy predictions and not a single Sell prediction Teva Pharmaceutical Industries Ltd ADR is an absolute favorite of our community.
With a target price of 31 € there is a positive potential of 22.53% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 25.3 €.
Our community identified positive and negative aspects for Teva Pharmaceutical Industries Ltd ADR stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Teva Pharmaceutical Industries Ltd ADR stock. On the other hand our users think that "Conscious of the environment" could be a problem in the future.
Pros and Cons of Teva Pharmaceutical Industries Ltd ADR in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
B****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Teva Pharmaceutical Industries Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd ADR | -1.170% | -5.882% | -10.490% | 70.100% | -4.833% | 219.202% | 174.384% |
| Bayer AG ADR | -4.900% | 3.209% | -20.902% | 73.874% | 9.659% | -30.072% | -26.336% |
| Novartis AG ADR | -0.740% | -3.226% | -2.527% | 35.000% | 13.924% | 73.077% | 86.207% |
| UCB S.A. | 0.040% | -1.770% | -9.081% | 41.873% | 7.540% | 219.765% | 220.407% |
Comments
Teva Pharmaceutical Industries (TEVA) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $41.00 price target on the stock, up from $40.00.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Truist Financial Corporation from $38.00 to $42.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $45.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat